ArticleScientific reports2026
Fc engineering of a fully humanized anti-CD147 monoclonal antibody enhances ADCC against T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) are aggressive hematologic malignancies with limited targeted treatment options and poor clinical outcomes across all age groups. CD147 is a multifunctional transmembrane glycoprotein that is highly expressed in various cancers, including T-cell leukemia and lymphoma. Its involvement in tumor progression and immune evasion makes CD147 a promising target for cancer immunotherapy. Monoclonal antibody-based immunotherapy can eliminate tumor cells not only by blocking oncogenic signaling pathways but also by engaging immune effector cells through antibody-dependent cellular cytotoxicity (ADCC). Enhancing ADCC has therefore emerged as a crucial strategy to enhance the therapeutic efficacy of anti-cancer antibodies. This study aimed to evaluate the functional activity of a fully humanized Fc-engineered anti-CD147 monoclonal antibody, HuM6-1B9-5M, which was designed to enhance ADCC by introducing five Fc mutations (L235V/F243L/R292P/Y300L/P396L). HuM6-1B9-5M was successfully expressed in HEK293T cells and retained CD147 binding activity and specificity comparable to those of the parental antibody. Biolayer interferometry against CD147 confirmed that Fc substitutions did not adversely affect antigen-binding affinity. Functional assays using PBMC effector cells demonstrated enhanced ADCC activity of HuM6-1B9-5M relative to the wild-type antibody (HuM6-1B9-WT) against Jurkat and SupT1 cell lines, representing T-ALL and T-LBL models, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.